Jan E. Berger, MD, MJ

A model of formulary decision making that evaluates medications based on usage could have significant implications for providers, consumers, and manufacturers.

The role of Pharmacy and Therapeutic committees in formulary creations raises concerns.

The United States has a pain management problem that stems from both treatment style and misuse; input from multiple stakeholder groups will be required to find a solution.

The cost of life-saving medications and the meaning of value are discussed.

Taking steps to improve medication adherence, starting with simple outreach efforts.

Drug shortages, whether caused by the manufacturers or the FDA, continue to escalate. The federal government has recently begun to address this concern.

When a new generic comes to market, we need to think not only about the financial implications but also about the message conveyed to patients.

Pharmacy benefit managers provide value for healthcare consumers, healthcare providers, and patients.

Medication reconciliation between the inpatient and outpatient settings might be possible through the pharmacy benefit management platform.

We need to get serious about programs to control hypertension.

Programs offering $4 generics lower costs for both payers and healthcare consumers, but these medications should go through the claims system to enable tracking.

Can value-based benefit design be used in specialty pharmacy to address costs and align incentives between patients and payers?

This study linked e-prescribing records to paid pharmacy claims to identify primary nonadherence rates and factors associated with unfilled prescriptions.

Among the commercially insured, pharmacy benefits define the availability, accessibility, and cost of prescription drugs.

In her editorial for this inaugural issue, the Editor-in-Chief lays out the philosophy and editorial scope of The American Journal of Pharmacy Benefits.

Effective, targeted communication is essential to the success of a value-based benefit design.

The Editor discusses how the results from comparative effectiveness research will affect the various constituents in the healthcare sector.